Summary of Century Therapeutics Conference Call Company Overview - **Company**: Century Therapeutics - **Ticker**: IPSC (NASDAQ) - **Focus**: Development of next-generation allogeneic cell therapies from programmable induced pluripotent stem cells (iPSCs) for autoimmune diseases and cancer [1][2] Core Technology and Pipeline - **Core Technology**: AlloVision technology, which enables the engineering of iPSC-derived cell therapies [2][5] - **Key Programs**: - **Century 308**: CD19 targeting CD4/CD8 alpha-beta CARiT cell therapy, currently in IND-enabling studies for B-cell-mediated diseases [3][5] - **Century 101**: CAR INK therapy targeting CD19, currently in clinical trials for autoimmune diseases [18][19] Clinical Development and Milestones - **Cash Runway**: Estimated to extend into Q4 2027, covering key clinical milestones [5] - **Clinical Trials**: - **Century 101**: In two Phase I trials for systemic lupus erythematosus (SLE), lupus nephritis, myositis, and systemic sclerosis [18][19] - **Century 308**: Expected to enter the clinic next year [5][18] Market Opportunity - **Autoimmune Disease Market**: Significant unmet medical need with tens of thousands of addressable patients in the U.S. for B-cell-mediated diseases [20][21] - **CAR T Therapy Market**: Current approved CAR T therapies have close to $5 billion in worldwide sales, but access remains a challenge with fewer than 30% of eligible patients receiving treatment [11][20] AlloVision Technology - **Immune Evasion**: AlloVision technology involves genetic edits to enhance the persistence of allogeneic cells and reduce rejection by the immune system [6][7] - **Holistic Protection**: AlloVision 5.0 includes multiple genetic modifications to protect against various immune rejection mechanisms [8][9] Preclinical and Clinical Data - **Century 308**: Demonstrated comparable functionality to primary T cells in preclinical studies, including IL-2 secretion and tumor control in mouse models [13][17] - **Century 101**: Established a safe and well-tolerated dose with effective B-cell depletion observed in clinical trials [22][23] Conclusion - **Future Outlook**: Century Therapeutics aims to leverage its iPSC platform and AlloVision technology to create impactful therapies for patients with severe diseases, with a focus on delivering clinical data throughout 2025 [24]

PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, will share a company presentation at the H.C. Wainwright 27th Annual Global Investment Conference. In addition, members of management will be available for meetings wi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40498 Century Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware ...

Exhibit 99.1 PHILADELPHIA, Aug. 14, 2025 -- Century Therapeutics, Inc. ('Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. "In the first half of 2025, we made important business decisions to ensure our capital resource allocation and pipeline development activities are centered on poten ...

PHILADELPHIA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ('Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. "In the first half of 2025, we made important business decisions to ensure our capital resource allocation and pipeline development activities are centered on p ...

Investors might want to bet on Century Therapeutics, Inc. (IPSC) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The pow ...

Core Viewpoint - Momentum investing focuses on "buying high and selling higher," contrasting with traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investing can be risky as stocks may lose momentum if future growth does not justify high valuations [1] - Identifying the right entry point for fast-moving stocks is challenging, and traditional momentum parameters may not always be reliable [1] Group 2: Bargain Stocks and Screening - Investing in bargain stocks with recent price momentum may be a safer strategy [2] - The Zacks Momentum Style Score is useful for identifying strong momentum stocks, while the 'Fast-Paced Momentum at a Bargain' screen helps find attractively priced fast-moving stocks [2] Group 3: Century Therapeutics, Inc. (IPSC) Analysis - Century Therapeutics, Inc. (IPSC) shows a four-week price change of 2.9%, indicating growing investor interest [3] - IPSC has gained 11.1% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe [4] - The stock has a beta of 1.78, suggesting it moves 78% more than the market in either direction [4] Group 4: Valuation and Earnings Estimates - IPSC has a Momentum Score of B, indicating a favorable time to invest [5] - The stock has a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which attract more investors [6] - IPSC is trading at a Price-to-Sales ratio of 0.45, suggesting it is undervalued at 45 cents for each dollar of sales [6] Group 5: Additional Investment Opportunities - Besides IPSC, there are other stocks that meet the 'Fast-Paced Momentum at a Bargain' criteria, presenting further investment opportunities [7] - Zacks offers over 45 Premium Screens tailored to different investing styles to help identify winning stock picks [8]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investors often face challenges in determining the right entry point for fast-moving stocks, which can lead to limited upside or downside risks [2] - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify such opportunities [3] Group 2: Century Therapeutics, Inc. (IPSC) Analysis - Century Therapeutics, Inc. (IPSC) has shown a price increase of 5.9% over the past four weeks, indicating growing investor interest [4] - The stock has gained 31.6% over the past 12 weeks, with a beta of 1.77, suggesting it moves 77% more than the market [5] - IPSC has a Momentum Score of A, indicating a favorable time to invest based on its momentum [6] Group 3: Earnings Estimates and Valuation - An upward trend in earnings estimate revisions has contributed to IPSC earning a Zacks Rank 2 (Buy), which is associated with strong momentum effects [7] - IPSC is trading at a Price-to-Sales ratio of 0.45, suggesting it is undervalued at 45 cents for each dollar of sales, providing room for growth [7] Group 4: Additional Investment Opportunities - Besides IPSC, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [8] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [9]

Group 1: Momentum Investing Overview - Momentum investing contrasts with the traditional "buy low and sell high" strategy, focusing instead on "buying high and selling higher" to capitalize on fast-moving stocks [1] - Identifying the right entry point for trending stocks can be challenging, as they may lose momentum if future growth does not justify their high valuations [1] Group 2: Investment Strategy - Investing in bargain stocks that have recently shown price momentum may be a safer approach [2] - The Zacks Momentum Style Score is useful for identifying strong momentum stocks, while the 'Fast-Paced Momentum at a Bargain' screen helps find attractively priced fast-moving stocks [2] Group 3: Century Therapeutics, Inc. (IPSC) Analysis - Century Therapeutics, Inc. (IPSC) has shown a price increase of 8.3% over the past four weeks, indicating growing investor interest [3] - IPSC has gained 0.8% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe [4] - The stock has a beta of 1.77, suggesting it moves 77% higher than the market in either direction, indicating fast-paced momentum [4] Group 4: Valuation and Earnings Estimates - IPSC has a Momentum Score of A, suggesting it is an opportune time to invest in the stock [5] - The stock has a Zacks Rank 2 (Buy) due to upward trends in earnings estimate revisions, which attract more investor interest [6] - IPSC is trading at a Price-to-Sales ratio of 0.42, indicating it is relatively cheap at 42 cents for each dollar of sales [6] Group 5: Additional Investment Opportunities - IPSC has significant potential for growth, and there are other stocks that meet the 'Fast-Paced Momentum at a Bargain' criteria [7] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify winning stock picks [8]

Core Insights - Century Therapeutics, Inc. is set to present at the EULAR 2025 Congress, showcasing its preclinical cell therapy pipeline targeting autoimmune diseases and cancer [1][2] Presentation Details - The first presentation will focus on CNTY-101, an iPSC-derived allogeneic CD19 targeting CAR-NK product, demonstrating significant B cell depletion and potential for B cell-driven autoimmune diseases [2] - The second presentation will cover the generation of various iPSC-derived CAR-NK, γδ CAR-T, and αβ CAR-T cells, highlighting their effectiveness in treating B cell-mediated autoimmune diseases [2] Company Overview - Century Therapeutics is a clinical-stage biotechnology company specializing in iPSC-derived cell therapies aimed at autoimmune diseases and cancers, leveraging cellular reprogramming and genetic engineering [3] - The company aims to develop off-the-shelf cell therapies to enhance patient access and improve treatment outcomes in autoimmune disease and cancer care [3]